Original document(67 pages)  中文版
    The invention described herein relates to new combretastatin derivatives obtained by total synthesis and having the following general formula (I) in which the groups are as defined in the description here below. Said compounds, though chemically related to the structure of cis/trans-combretastatin, do not always bind tubulin, but nevertheless exhibit cytotoxic activity of interest in the oncological field as anticancer and/or antiangiogenic agents.
Application Number
申请号		 200480020757 Application Date
申请日		 2004.07.06
Title 名称 Combretastatin derivatives with cytotoxic action
Publication Number
公开号		 1826330 Publication Date
公开日		 2006.08.30
Approval Pub. Date Granted Pub. Date
International Classification 分类号 C07D261/12,C07D261/08,C07D307/79,C07D333/54,C07C43/215,C07C43/23,C07D231/56,C07D307/71,C07D333/44,C07F9/655,C07F9/6553,C07F7/18,A61K31/09,A61K31/41,A61K31/343
Applicant(s) Name
申请人		 Sigma Tau Ind Farmaceuti
Address 地址
Inventor(s) Name 发明人 Simoni Daniele, Romagnoli Romeo, Giannini Giuseppe, Alloatti Domenico
Attorney & Agent 代理人 chen dielan

  
Pi-3 kinase inhibitor prodrugs
Method for preparing 3-halo-4,5-dihydro-1H-pyrazoles
Diamine derivatives
Tetrahydropyranyl cyclopentyl heterocyclic amide modulators of chemokine receptor activity
Process for producing 1,2,4-triazole compound and intermediate therefor
Cyclohexanecarboxylic acid compound
Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone and method thereof
Therapeutic agent for senile dementia
2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.